Literature DB >> 1543704

Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma.

K Funato1, R Yoda, H Kiwada.   

Abstract

Large multilamellar vesicles (MLV) composed of hydrogenated egg phosphatidylcholine (HEPC), cholesterol (CH), and dicetyl phosphate (DCP) rapidly release part of an entrapped aqueous marker when incubated with fresh rat plasma and thus have severely limited usefulness as drug carriers. The mechanisms causing the instability of liposomes in plasma were investigated in this study. The leakage of liposomal constituents was completely inhibited by pre-heating at 56 degrees C for 30 min with plasma or by treating with EDTA, K-76COOH, or anti-C3 antiserum but was not inhibited with EGTA/MgCl2. These results indicated that the destabilization of liposomes in fresh rat plasma was induced by activation of the alternative complement pathway (ACP). Furthermore, the complement third component (C3) was detected from the liposomes incubated with fresh plasma by SDS-PAGE followed by Western blotting and immune detection. The C3b deposited on the liposomal surface via ACP was rapidly cleaved to iC3b. The results obtained in the present study suggest a possibility that the liposomes composed of HEPC (without any surface modification) may be effective carriers for macrophages because C3b and its degradative products, iC3b are related to the opsonic function on phagocytosis of foreign particles by macrophages.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543704     DOI: 10.1016/0005-2736(92)90087-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  23 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

3.  Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism.

Authors:  H Harashima; S Komatsu; S Kojima; C Yanagi; Y Morioka; M Naito; H Kiwada
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

4.  Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo.

Authors:  Okhil K Nag; Vivek R Yadav; Andria Hedrick; Vibhudutta Awasthi
Journal:  Int J Pharm       Date:  2013-02-16       Impact factor: 5.875

5.  Distinction between the depletion of opsonins and the saturation of uptake in the dose-dependent hepatic uptake of liposomes.

Authors:  H Harashima; K Sakata; H Kiwada
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

6.  Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes.

Authors:  H Harashima; K Sakata; K Funato; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

7.  Plasma factor triggering alternative complement pathway activation by liposomes.

Authors:  K Funato; C Yamashita; J Kamada; S Tominaga; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

Review 8.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.